ClinicalTrials.gg
RecruitingNCT03895879TODORAUpdated Apr 18, 2024

Use of Tocilizumab Drug Levels to Optimize Treatment in RA

A Phase 4 interventional study of Tocilizumab and Tocilizumab in Rheumatoid Arthritis, sponsored by Reade Rheumatology Research Institute. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Reade Rheumatology Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Planned enrollment
55th of 110
98 · median 97
Started
2020
with 1 other
Phase 4
32 of 110
2 open now
Registered
101st of 110
by date

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 55th largest by planned enrollment, is one of 2 that started in 2020, is one of 32 in phase 4, and was the 101st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Tocilizumab concentrations above 1 mg/L are likely to be sufficient for normalizing C-reactive protein (CRP) production in patients with rheumatoid arthritis (RA). In practice, however, a large variability in the concentrations of tocilizumab is found, and a large proportion of patients treated with tocilizumab subcutaneously (sc) have concentrations far above 1 mg/L. These patients can probably lower their doses without losing clinical response.

A 52 weeks non-inferiority, multicenter, randomized controlled study will be performed to investigate whether patients with RA with serum trough concentrations of tocilizumab higher than 15 mg/L can increase their dosing interval to every two weeks without losing clinical response. Patients with relatively high trough concentrations will be randomly assigned to continuation of the standard dose or to increase dosing interval to every two weeks. The main objective is to investigate the difference in mean time weighted Disease Activity Score in 28 joints, including erythrocyte sedimentation rate (DAS28-ESR) between the two groups after 28 weeks. It is expected that patients with relatively high trough concentrations can safely increase their dosing interval without losing response.

Read the detailed description

Tocilizumab is a humanized monoclonal antibody targeting the IL-6 receptor (IL-6R). It has proven to be effective in reducing inflammation and symptoms in rheumatoid arthritis (RA). The registered standard dose of tocilizumab subcutaneously (sc) is 162 mg weekly for every patient. All patients diagnosed with RA and treated with tocilizumab sc receive the same dose, so treatment with expensive biologicals is currently based on a 'one size fits all' approach. Because of the large inter-individual variability in the pharmacokinetics of tocilizumab this standard dose results in a wide range of serum concentrations. In the search to optimize the dose for individual patients it was demonstrated that serum levels of 1 mg/L of tocilizumab are adequate to block the IL-6 receptor systemically, as indicated by a reduction in CRP levels in patients with these low trough concentrations. Therefore, a substantial proportion of patients is likely to be overexposed to tocilizumab. This overtreatment is a waste of health care resources and might be associated with an increased risk of adverse events, mainly infections.

We believe that overexposure can be reduced effectively by making use of the drug concentrations found in the serum of individual patients. Our hypothesis is therefore that reducing the dose in the setting of therapeutic drug monitoring (TDM) does not affect clinical disease activity and safety, while it will reduce costs.

Based on previous studies we believe that a concentration around 5 mg/L is sufficient to reach the maximal treatment effect. Therefore tapering strategy was developed aiming for serum concentrations around 5 mg/L. Monte Carlo modelling was performed to determine the cut-off concentration for interval prolongation to be used in this study. Simulations were performed and it was found that patients with trough concentrations above 15 mg/L can safely prolong their dosing interval, as this will result in levels around 5 mg/L in the majority of patients.

This study is a 52 weeks randomised, multicenter, non-inferiority trial in rheumatoid arthritis patients treated with subcutaneous tocilizumab 162 mg weekly for at least the previous 6 months. After informed consent is obtained during the baseline visit, blood will be drawn to measure drug trough concentrations. Patients with a tocilizumab concentration above 15 mg/L will be randomly assigned to dose reduction by increasing their dosing-interval from once every week to once every two weeks, or to continuation of their tocilizumab dose (standard dose). After randomization, patients are followed for a period of 52 weeks. Data regarding disease status and functioning will be collected during the baseline visit, and 12, 28, 40, and 52 weeks thereafter. Blood will also be drawn from the patients during these visits. All patients with concentrations below 15 mg/L during the first study visit will not be randomized and all continue standard treatment. Only one follow-up visit, after 52 weeks, will be performed in this group of patients.

Patients can also choose to participate in a sub-study where the finger prick developed by Sanquin (Amsterdam) will be validated to measure tocilizumab drug levels. This part of the study will comprise performing three finger pricks. These finger pricks will be performed during the visit at week 12 with the help of a nurse, and at home during the two weeks after this visit.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Tocilizumab
  • Therapeutic Drug Monitoring
  • Drug level
  • Dose reduction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rheumatoid arthritis according to the American College of Rheumatology (ACR) 1987 or 2010 criteria;
  • Current use of subcutaneous tocilizumab 162 mg weekly, for at least the previous 6 months;
  • The treating rheumatologist is convinced of the benefit of tocilizumab continuation;
  • Written .

Exclusion criteria

Exclusion Criteria:

  • A scheduled surgery in the next 52 weeks or other pre-planned reasons for treatment discontinuation;
  • Changes in the treatment with and DMARDs such as methotrexate in the past three months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Intervention

    Tocilizumab administered every 2 weeks

    Drug: Tocilizumab

  • Active comparator
    Control

    Tocilizumab administered every week

    Drug: Tocilizumab

  • Active comparator
    Standard dose (screening < 15 mg/L)

    Tocilizumab administered every week

    Drug: Tocilizumab

Interventions

  • Tocilizumab sc (162 mg) once every 2 weeks

  • Tocilizumab sc (162 mg) once every week

06

What researchers measure

Primary outcomes

  1. DAS28-ESR

    The difference in mean time weighted DAS28 after 28 weeks between patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 weeks

Secondary outcomes

  1. DAS28-ESR

    The difference in mean time weighted DAS28 after 52 weeks between patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 52 weeks

  2. Clinical Disease Activity Index (CDAI)

    The difference in CDAI-score after 28 and 52 weeks between the patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 and 52 weeks

  3. Simple Disease Activity Index (SDAI)

    The difference in SDAI-score after 28 and 52 weeks between the patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 and 52 weeks

  4. Health Assessment Questionnaire (HAQ)

    The difference in HAQ-score after 28 and 52 weeks between the patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 and 52 weeks

  5. Direct medical costs of TDM

    The difference in direct medical costs of TDM compared to the standard treatment regimen.

    Time frame: 52 weeks

  6. Number of flares

    The difference in number of flares at 28 and 52 weeks between patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 and 52 weeks

  7. Number and severity of adverse events

    The difference in number and severity of adverse events at 28 and 52 weeks between patients undergoing concentration-guided dose reduction or standard dosing.

    Time frame: 28 and 52 weeks

  8. Drug level

    The difference in drug levels in the intervention group between week 0 and 52.

    Time frame: 52 weeks

  9. Patient perspective towards therapeutic drug monitoring

    A questionnaire will be used to evaluate the perspective of patients towards therapeutic drug monitoring.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20. PubMed 27440258 ↗
  • l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22. PubMed 28939629 ↗
  • Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010 Jul;50(7):754-66. doi: 10.1177/0091270009350623. Epub 2010 Jan 23. PubMed 20097931 ↗
  • Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yague J, Sanmarti R, Huitema ADR, Soy D. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018 Apr;84(4):716-725. doi: 10.1111/bcp.13500. Epub 2018 Feb 7. PubMed 29314183 ↗

Individual participant data

Plan to share: Yes — To avoid duplication of research, the data gathered in this study will be shared once all desirable data analysis have been performed and the results are published.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Six months after the final publication from the study is published the data will be shared.

Access criteria: Researchers with demonstrable interest in autoimmunity, biologicals, or TDM can contact the investigators of the trial if they are interested in gaining access to the data. Depending on their research objectives the data will be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2024, 57 months after the start.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 57 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
Mar 29, 2019
StartActual
Mar 1, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03895879
Lead sponsor
Reade Rheumatology Research Institute
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Mar 1, 2020
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 18, 2024

Study contacts

Femke Hooijberg, MD
Contact
f.hooijberg@reade.nl
0031 20 2421633
Sadaf Atiqi, MD
Contact
s.atiqi@reade.nl
0031 20 2421641
Gertjan Wolbink, MD, PhD
principal investigator · Reade Rheumatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion